Dimerix Ltd
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is… Read more
Dimerix Ltd (SBMJF) - Total Liabilities
Latest total liabilities as of June 2025: $77.80 Million USD
Based on the latest financial reports, Dimerix Ltd (SBMJF) has total liabilities worth $77.80 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Dimerix Ltd - Total Liabilities Trend (2021–2025)
This chart illustrates how Dimerix Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Dimerix Ltd Competitors by Total Liabilities
The table below lists competitors of Dimerix Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grupo Minsa S.A.B. de C.V
MX:MINSAB
|
Mexico | MX$2.20 Billion |
|
Spero Therapeutics Inc
NASDAQ:SPRO
|
USA | $27.68 Million |
|
IGPTF
PINK:IGPTF
|
USA | $3.86 Billion |
|
Hoteles City Express S.A.B. de C.V
PINK:HOCXF
|
USA | $5.25 Billion |
|
CHT Security Co., Ltd.
TW:7765
|
Taiwan | NT$1.01 Billion |
|
Izmir Demir Celik Sanayi AS
IS:IZMDC
|
Turkey | TL27.91 Billion |
|
Douglas Elliman Inc
NYSE:DOUG
|
USA | $365.79 Million |
|
Sukgyung AT Co. Ltd.
KQ:357550
|
Korea | ₩10.47 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down Dimerix Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.85 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dimerix Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dimerix Ltd (2021–2025)
The table below shows the annual total liabilities of Dimerix Ltd from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $77.80 Million | +459.98% |
| 2024-06-30 | $13.89 Million | +17.79% |
| 2023-06-30 | $11.79 Million | +468.57% |
| 2022-06-30 | $2.07 Million | -73.91% |
| 2021-06-30 | $7.95 Million | -- |